Literature DB >> 17414214

Fibrinolysis and the risk of venous and arterial thrombosis.

Mirjam E Meltzer1, Carine J M Doggen, Philip G de Groot, Frits R Rosendaal, Ton Lisman.   

Abstract

PURPOSE OF REVIEW: The fibrinolytic system is often regarded as just an innocent bystander in the pathogenesis of venous and arterial thrombosis, while (hyper)coagulation as a risk factor has been studied extensively. In this review, we evaluated studies that investigated the association between fibrinolysis and thrombosis. RECENT
FINDINGS: There is some evidence for an association between impaired overall fibrinolytic activity and increased risk of venous or arterial thrombosis. Plasminogen levels were found not to be related to thrombosis. Plasma levels of tissue-type plasminogen activator were related to arterial thrombosis in a number of studies but not to venous thrombosis. Thrombin activatable fibrinolysis inhibitor levels appeared to be associated with venous thrombosis. Studies on the association between thrombin activatable fibrinolysis inhibitor or plasminogen activator inhibitor-1 and arterial thrombosis had conflicting results.
SUMMARY: Current evidence on an association between fibrinolysis and thrombosis is inconclusive. Although overall assays point to an association, not all individual factors have an association with thrombosis. Most importantly, plasminogen deficiency is not related to thrombosis, which suggests that the fibrinolytic system as a whole is unimportant in the occurrence of thrombosis. Certain components of the fibrinolytic system, however, appear to be involved in processes unrelated to fibrin degradation but related to other processes important in the development of thrombosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414214     DOI: 10.1097/MOH.0b013e3280dce557

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  6 in total

1.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Thrombophilia: 2009 update.

Authors:  Pat Foy; Stephan Moll
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

3.  Plasminogen on the surfaces of fibrin clots prevents adhesion of leukocytes and platelets.

Authors:  V K Lishko; I S Yermolenko; T P Ugarova
Journal:  J Thromb Haemost       Date:  2009-01-22       Impact factor: 5.824

4.  Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity.

Authors:  Anna Paola Cellai; Donatella Lami; Emilia Antonucci; Agatina Alessandrello Liotta; Angela Rogolino; Sandra Fedi; Claudia Fiorillo; Matteo Becatti; Caterina Cenci; Rossella Marcucci; Rosanna Abbate; Domenico Prisco
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

Review 5.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

6.  Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy.

Authors:  Yassene Mohammed; Carolina E Touw; Banne Nemeth; Raymond A van Adrichem; Christoph H Borchers; Frits R Rosendaal; Bart J van Vlijmen; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2022-01-06       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.